Advisor - Computational Biology at Eli Lilly and Company

Boston, Massachusetts, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Pharmaceuticals, Gene TherapyIndustries

Requirements

PhD degree in Bioinformatics, Computational Biology, Genomics, or related scientific fields
Minimum 2 years industry experience in bioinformatics with focus on NGS data analysis and/or structural modeling

Responsibilities

Design, execute, and maintain robust bioinformatics pipelines for analyzing bulk and single-cell RNA sequencing, AAV integration analysis, vector genome sequencing, and capsid library screening data
Perform end-to-end NGS data analysis including quality control, variant calling, differential expression analysis, and biological interpretation
Develop computational methods for AAV vector characterization, including integration site analysis, biodistribution assessment, and disease-/tissue-specific biological interpretation
Support AAV capsid engineering efforts through computational analysis of structure-function relationships and receptor binding prediction
Analyze transcriptomic and proteomic datasets to identify therapeutic targets and biomarkers for gene therapy applications
Communicate and present experimental findings to internal teams and Lilly stakeholders
Demonstrate cross-functional collaboration within Lilly Gene Therapy and broader Lilly Research Laboratories (including lab-based scientists), ensuring project milestones are met while maintaining adaptability to evolving research priorities
Report to Executive Director – Vector Engineering and Delivery to evaluate top performing AAV vectors that are fit-for-purpose on select CNS indications

Skills

Key technologies and capabilities for this role

NGSbioinformaticsRNA-seqsingle-cell RNA-seqAAVcapsid engineeringpayload engineeringstructural modelinggenomic analysisvector genome sequencing

Questions & Answers

Common questions about this position

What is the minimum education required for this role?

A PhD degree in Bioinformatics or Computational Biology is required.

What are the key responsibilities of this position?

The role involves designing bioinformatics pipelines for NGS data analysis, performing end-to-end analysis including quality control and variant calling, developing methods for AAV vector characterization, supporting capsid engineering, analyzing transcriptomic and proteomic data, and communicating findings to teams.

Is this a remote position or does it require working in an office?

This information is not specified in the job description.

What is the salary or compensation for this role?

This information is not specified in the job description.

What kind of team will I be working with?

You will work collaboratively with cross-functional teams including molecular biology, vector engineering, and pre-clinical development, reporting to the Executive Director – Vector Engineering and Delivery, within the Lilly Gene Therapy Discovery and Platform Research team.

Eli Lilly and Company

Develops and delivers prescription medicines globally

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that focuses on discovering, developing, and delivering medicines to improve health. The company has a long history of scientific achievements, including the creation of insulin, the first life-saving treatment for diabetes. Lilly's operations involve extensive research and development to create new medications and enhance existing ones, ensuring they are safe and effective. Their products are primarily prescription medicines sold to healthcare providers for various medical conditions, including diabetes, cancer, and pain management. What sets Lilly apart from its competitors is its strong commitment to ethical practices and the protection of its products from counterfeiting. The company's goal is to enhance lives through innovative medical solutions while maintaining high standards of quality and ethics.

Indianapolis, IndianaHeadquarters

1876Year Founded

$1,180.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Risks

Competition from Novo Nordisk's Ozempic may impact tirzepatide's market share.

Potential construction delays in Indiana could affect GLP-1 drug production timelines.

Regulatory challenges may hinder Kisunla's expansion in new Alzheimer's markets.

Differentiation

Eli Lilly's rich history includes the first life-saving insulin treatment.

Lilly's strategic partnerships enhance its position in neurodegenerative disease treatments.

FDA approval of Zepbound opens new therapeutic markets for sleep disorder treatments.

Upsides

Lilly's $9 billion complex in Indiana boosts GLP-1 drug production capacity.

Kisunla's approval in China expands Lilly's Alzheimer's treatment market in Asia.

Collaboration with EVA Pharma enhances Lilly's reputation as socially responsible.

Land your dream remote job 3x faster with AI

Try Jobo Free